Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation.
Bolwell B, Vredenburgh J, Overmoyer B, Gilbert C, Chap L, Menchaca DM, Cruickshank S, Glaspy J. Bolwell B, et al. Among authors: menchaca dm. Bone Marrow Transplant. 2000 Jul;26(2):141-5. doi: 10.1038/sj.bmt.1702465. Bone Marrow Transplant. 2000. PMID: 10918423 Clinical Trial.
Rapid hematopoietic recovery after multicycle high-dose chemotherapy: enhancement of filgrastim-induced progenitor-cell mobilization by recombinant human stem-cell factor.
Basser RL, To LB, Begley CG, Maher D, Juttner C, Cebon J, Mansfield R, Olver I, Duggan G, Szer J, Collins J, Schwartz B, Marty J, Menchaca D, Sheridan WP, Fox RM, Green MD. Basser RL, et al. Among authors: menchaca d. J Clin Oncol. 1998 May;16(5):1899-908. doi: 10.1200/JCO.1998.16.5.1899. J Clin Oncol. 1998. PMID: 9586908 Clinical Trial.
Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer.
Basser RL, Rasko JE, Clarke K, Cebon J, Green MD, Grigg AP, Zalcberg J, Cohen B, O'Byrne J, Menchaca DM, Fox RM, Begley CG. Basser RL, et al. Among authors: menchaca dm. Blood. 1997 May 1;89(9):3118-28. Blood. 1997. PMID: 9129014 Free article. Clinical Trial.
The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation.
Schuster MW, Beveridge R, Frei-Lahr D, Abboud CN, Cruickshank S, Macri M, Menchaca D, Holden J, Waller EK. Schuster MW, et al. Among authors: menchaca d. Exp Hematol. 2002 Sep;30(9):1044-50. doi: 10.1016/s0301-472x(02)00878-0. Exp Hematol. 2002. PMID: 12225796 Free article. Clinical Trial.
Clinical applications of filgrastim and stem cell factor in vivo and in vitro.
Morstyn G, Glaspy J, Shpall EJ, LeMaistre F, Briddell R, Menchaca D, Lill M, Jones RB, Tami J, Brown S, et al. Morstyn G, et al. Among authors: menchaca d. J Hematother. 1994 Winter;3(4):353-5. doi: 10.1089/scd.1.1994.3.353. J Hematother. 1994. PMID: 7537611 Review. No abstract available.
19 results